Status:

RECRUITING

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Lead Sponsor:

University of Florida

Collaborating Sponsors:

Emory University

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Hypertension, Resistant to Conventional Therapy

Eligibility:

All Genders

18-100 years

Phase:

PHASE4

Brief Summary

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer a...

Detailed Description

One hundred twenty patients with treatment-resistant hypertension will be enrolled. A total of 34 patients (17 from each treatment arm), who are participants in the main study, will also be enrolled i...

Eligibility Criteria

Inclusion Criteria:

  • Age ≥18 years
  • Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic.
  • The participant agrees to have all study procedures performed

Exclusion Criteria:

  • Known hypersensitivity or contraindication to minocycline or other tetracyclines
  • Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
  • Estimated glomerular filtration rate (eGFR) of <45mL/min/1.73m2, using the MDRD equation
  • Known secondary hypertension
  • History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year
  • History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of >20 mm Hg or DBP of >10 mm Hg within 3 minutes of standing) in the past year
  • History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months
  • Evidence of alcoholism or drug abuse
  • Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)
  • Current pregnancy or anticipated pregnancy during the study.

Key Trial Info

Start Date :

January 8 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2028

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT06246396

Start Date

January 8 2025

End Date

July 1 2028

Last Update

March 6 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UF Clinical Research Center (UF CRC) - CTSI

Gainesville, Florida, United States, 32610